For instance, EGFR mutations, which exist in nearly 50% of Chinese patients with ADC [6], are well defined as lung cancer drivers and are routinely assessed at diagnosis as a selective biomarker for first-line targeted therapy with EGFR inhibitors [7]. The gene discussed is EGFR; the disease is lung cancer.